Drug updated on 12/11/2024
| Dosage Form | Capsule (oral; 200 mg) |
| Drug Class | Complement factor B inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)
- Indicated for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) 1.5 g/g.
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- The abstract does not provide detailed effectiveness outcomes for iptacopan (FABHALTA) in the treatment of eculizumab-refractory Paroxysmal Nocturnal Hemoglobinuria (PNH) but mentions its inclusion in a systematic review.
- No direct comparisons or specific data on the effectiveness of iptacopan relative to other drugs like pegcetacoplan or danicopan are mentioned, and there are no subgroup-specific effectiveness outcomes provided.
- There is no safety information available in the reviewed documents regarding FABHALTA for the treatment of eculizumab refractory PNH.
- There is no population types or subgroups information available in the reviewed documents regarding FABHALTA for the treatment of eculizumab refractory PNH.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Fabhalta (iptacopan) Prescribing Information. | 2024 | Novartis Pharmaceuticals Corporation, East Hanover, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction | 2023 | SAGE Open Medicine |